- Home
- MGLD vs DBVT Comparison
MGLD vs DBVT Comparison
Compare MGLD & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- DBVT
- Stock Information
- Founded
- MGLD 1996
- DBVT 2002
- Country
- MGLD United States
- DBVT France
- Employees
- MGLD N/A
- DBVT N/A
- Industry
- MGLD Finance/Investors Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGLD Finance
- DBVT Health Care
- Exchange
- MGLD Nasdaq
- DBVT Nasdaq
- Market Cap
- MGLD 60.7M
- DBVT 67.8M
- IPO Year
- MGLD N/A
- DBVT N/A
- Fundamental
- Price
- MGLD $1.34
- DBVT $0.62
- Analyst Decision
- MGLD
- DBVT Strong Buy
- Analyst Count
- MGLD 0
- DBVT 2
- Target Price
- MGLD N/A
- DBVT $6.00
- AVG Volume (30 Days)
- MGLD 2.6K
- DBVT 2.0M
- Earning Date
- MGLD 11-19-2024
- DBVT 11-06-2024
- Dividend Yield
- MGLD N/A
- DBVT N/A
- EPS Growth
- MGLD N/A
- DBVT N/A
- EPS
- MGLD N/A
- DBVT N/A
- Revenue
- MGLD $32,511,000.00
- DBVT $12,515,000.00
- Revenue This Year
- MGLD N/A
- DBVT N/A
- Revenue Next Year
- MGLD N/A
- DBVT $2,860.00
- P/E Ratio
- MGLD N/A
- DBVT N/A
- Revenue Growth
- MGLD N/A
- DBVT 125.54
- 52 Week Low
- MGLD $0.78
- DBVT $0.50
- 52 Week High
- MGLD $1.92
- DBVT $2.14
- Technical
- Relative Strength Index (RSI)
- MGLD 51.79
- DBVT 33.51
- Support Level
- MGLD $1.15
- DBVT $0.60
- Resistance Level
- MGLD $1.47
- DBVT $0.81
- Average True Range (ATR)
- MGLD 0.08
- DBVT 0.05
- MACD
- MGLD 0.01
- DBVT -0.02
- Stochastic Oscillator
- MGLD 63.89
- DBVT 3.95
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.